AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$CYTK

Landry Robert E sold $75K of CYTK

Landry Robert E sold 1,000 shares of CYTOKINETICS INC (CYTK) at $74.66 on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Landry Robert E
Published Sep 11, 2026, 11:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
high confidence
Mentioned
$CYTK
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The sale is routine and unlikely to trigger trading activity, but investors may monitor for patterns in insider behavior.

02

Market read

A modest insider sale with limited market impact; primarily of interest to existing shareholders.

03

What to watch

Potential upcoming clinical trial results or regulatory news not disclosed in the filing.

Relevance 2/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions. Directors often use 10b5-1 plans for scheduled sales.

Company-level read

Ticker impact

$CYTKNeutralHigh confidence
Context

Director Robert E. Landry sold 1,000 CYTK shares for $74.66 each, reducing his stake to 9,184 shares.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

The transaction size (~$75k) is modest for a director and disclosed via a 10b5-1 plan, suggesting routine portfolio rebalancing rather than a red flag.

Market effects

Sector

None; Cytokinetics operates in biotech, and the insider sale is too small to affect sector sentiment.

Regional

None; the filing is U.S.-specific and does not influence broader regional markets.

Global

None; limited to CYTK shareholders.

Counterpoint

What could challenge this read

If the director anticipates upcoming negative news, even a small sale could precede a price decline.

Key entities

  • Company
    Cytokinetics Inc

    Biopharmaceutical company developing cardiac and skeletal muscle therapeutics.

  • Insider
    Robert E. Landry

    Director of Cytokinetics who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

SEP 12
$CYTKMedAI 8/10

Cytokinetics (CYTK) Shares In Focus After New Phase 3 Aficamten Data

Cytokinetics (CYTK) reported detailed Phase 3 trial results for aficamten, showing efficacy and safety in hypertrophic cardiomyopathy. The company plans to file a supplemental drug application, aiming to expand its cardiology franchise. Cytokinetics has a market cap of $10.3 billion and focuses on muscle-related diseases. Regulatory uncertainty and a small pipeline remain risks.

simplywall.st2 min
SEP 11
$CYTKMed

Cantor Fitzgerald reiterates Overweight on Cytokinetics stock

Cantor Fitzgerald reiterated an Overweight rating on Cytokinetics (CYTK), citing strong commercial and regulatory outlooks. The stock has risen 38% over the past year, trading at $73.62 with a $10.23B market cap. Analysts have raised earnings estimates, though profitability is not expected this year. Management expects 50% new prescription share by year-end and potential REMS relaxation. Cytokinetics reported Q2 sales of $25.3M for Myqorzo, exceeding estimates. Barclays and Citizens raised price

investing.com2 min
SEP 8
$CYTKMedAI 8/10

Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

finance.yahoo.com2 min
SEP 2
$CYTKMedAI 8/10

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics (CYTK) presented additional results from ACACIA-HCM and MAPLE-HCM studies at the European Society of Cardiology Congress 2026, showing aficamten's benefits in non-obstructive HCM (nHCM) and superiority over metoprolol in obstructive HCM (oHCM). CYTK plans to submit an sNDA for aficamten in nHCM in Q4 2026. Myqorzo (aficamten) faces competition from Bristol Myers Squibb's (BMY) Camzyos and Edgewise Therapeutics' (EWTX) EDG-7500. CYTK shares are up 12.4% YTD, trading at 26.6X forward

finance.yahoo.com3 min
AUG 31
$CYTKMedAI 9/10

What's Going On With Cytokinetics Stock Today? - Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) reported positive results from its ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy, meeting primary endpoints and showing improvements in symptoms and exercise performance. The drug showed benefits in five key areas, but some safety concerns were noted. Cytokinetics plans to file for FDA approval in Q4 2026. Shares fell 3.19% to $69.79.

benzinga.com2 min